Ajay K. Nooka
Emory University/Winship Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ajay K. Nooka as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:29 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05208307 · Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaEmory University · recruiting · Plasma Cell Myeloma · principal investigator
- Ph2NCT05204160 · Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell TherapyEmory University · withdrawn · Plasma Cell Myeloma
- Ph3NCT04361552 · Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)Emory University · withdrawn · Cerebrovascular Accident, Chronic Obstructive Pulmonary Disease, Chronic Renal Failure
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:29 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · fiscal years 2009 to 2026
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:29 UTC. The ranking covers the 200 most relevant of 32 PubMed records, and a shared surname and initials can bring in a namesake. All 32 on PubMed
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.N Engl J Med · 20161,254 citationsRCR 41.8
- Teclistamab in Relapsed or Refractory Multiple Myeloma.N Engl J Med · 20221,126 citationsRCR 79.2
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 2023686 citationsRCR 61.1
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.Lancet Oncol · 2020666 citationsRCR 30.2
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.Nat Med · 2023617 citationsRCR 54.5
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.N Engl J Med · 2019550 citationsRCR 19.6
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR.Haematologica · 2018226 citationsRCR 8.1
- Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.Clin Lymphoma Myeloma Leuk · 2020139 citationsRCR 6.6
- 129 citationsRCR 7.1
- Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.J Clin Oncol · 2023123 citationsRCR 11.4